Background Randomised placebo-controlled trials have shown that daily oral pre-exposure
prophylaxis (PrEP) with tenofovir–emtricitabine reduces the risk of HIV infection. However …

In 2001, 59% of people in the United Kingdom with HIV who were starting treatment had
CD4 lymphocyte counts of fewer than 200 cells/μl, 1 mostly because of late diagnosis. We …

Objective: To characterise clinical, investigative, and prognostic features of women referred
with chest pain who subsequently underwent coronary angiography. Design: Analysis of all …

Background Deaths in HIV-positive people have decreased since the introduction of highly
active antiretroviral therapy (HAART) in 1996. Fewer AIDS-related deaths and an ageing …

Objective: To identify opportunities for earlier HIV diagnosis within primary and secondary
care settings in the UK in Africans with newly diagnosed HIV infection. Methods: A survey of …

Improved methods for targeting HIV testing among patients most likely to be infected are
required; HIDES I aimed to define the methodology of a European wide study of HIV …

Background In Europe, HIV disproportionately affects men who have sex with men (MSM),
people who inject drugs (PWID), prisoners, sex workers, and transgender people …

Introduction In recent years, HIV testing frequency has increased, resulting in more people
being diagnosed during seroconversion with a temporarily low CD4 count. Using the current …

Abstract Background Pre-exposure prophylaxis (PrEP) has proven biological efficacy to
reduce the sexual acquisition of the human immunodeficiency virus (HIV). The PROUD …

Abstract Background Pre-exposure prophylaxis (PrEP) is a novel HIV prevention method
whereby HIV-negative individuals take the drugs tenofovir and emtricitabine to prevent HIV …